FDA Approvals of Immunotherapy in Gynecology Oncology
December 7th 2022In this seventh episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, walk through a timeline of FDA approvals of immunotherapy approaches in gynecologic oncology and discuss associated toxicities to be aware of as well as how to manage them.
Read More
Immunotherapy and You: Checkpoint Inhibitors in Gynecologic Cancers
November 30th 2022In this sixth episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, highlight the success seen with checkpoint inhibitors in gynecologic cancers, biomarkers of interest, and recent approvals in the space.
Read More
Immunotherapy and You: Understanding the PD-L1 Blockade
November 23rd 2022In this fifth episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, discuss PD-1 blockade, potential biomarkers of response to treatment with immunotherapy, and the potential for these agents in the neoadjuvant setting.
Read More
Long-term Survival Data With Immunotherapy in Gynecologic Cancers
November 16th 2022In this fourth episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, highlight long-term survival data reported with immunotherapy approaches in patients with gynecologic cancers.
Read More
Immunotherapy and You: Gynecologic Treatment Efficacy From a Patient’s Perspective
November 2nd 2022In this second episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, discuss the safety and efficacy of immunotherapy vs standard chemotherapy in patients with gynecologic cancers.
Read More
Immunotherapy and You: How Has Immunotherapy Changed Gynecologic Cancer Practice?
October 26th 2022In this first episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, explain how immunotherapy has changed practice for the treatment of patients with gynecologic cancers.
Read More
Taking Action to Individualize Ovarian Cancer Care: Key Takeaways
September 7th 2022In this fifth episode of OncChats: Taking Action to Individualize Ovarian Cancer Care, John Nakayama, MD, and Christopher Morse, MD, share key takeaways from their discussion on how to best individualize care for patients with ovarian cancer.
Read More
Taking Action to Individualize Ovarian Cancer Care: Excitement Surrounding PARP Inhibition
August 31st 2022In this fourth episode of OncChats: Taking Action to Individualize Ovarian Cancer Care, John Nakayama, MD, and Christopher Morse, MD, discuss key developments made with PARP inhibitors in the ovarian cancer treatment paradigm.
Read More
Taking Action to Individualize Ovarian Cancer Care: Somatic Vs Germline Testing
August 24th 2022In this third episode of OncChats: Taking Action to Individualize Ovarian Cancer Care, John Nakayama, MD, and Christopher Morse, MD, explain the differences between germline and somatic testing in patients with ovarian cancer.
Read More
Taking Action to Individualize Ovarian Cancer Care: Counseling Those with BRCA Mutations
August 17th 2022In this second episode of OncChats: Taking Action to Individualize Ovarian Cancer Care, John Nakayama, MD, and Christopher Morse, MD, discuss how to counsel patients with ovarian cancer whose tumors harbor BRCA mutations.
Read More
Taking Action to Individualize Ovarian Cancer Care: Effect of BRCA on Treatment
August 10th 2022In this first episode of OncChats: Taking Action to Individualize Ovarian Cancer Care, John Nakayama, MD, and Christopher Morse, MD, discuss how BRCA mutational status affects treatment decisions for patients with ovarian cancer.
Read More